FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results

The Independent The Independent

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

Read full article at The Independent →